Purdue University

Eli Lilly and Purdue University Forge $250 Million Partnership to Accelerate Pharmaceutical Innovation

10 days ago

• Eli Lilly and Purdue University have announced an expanded collaboration worth up to $250 million to advance pharmaceutical research and development across multiple therapeutic areas. • The strategic partnership aims to combine Lilly's industry expertise with Purdue's academic research capabilities to address unmet medical needs and accelerate drug discovery timelines. • This investment represents one of the largest industry-academic collaborations in the pharmaceutical sector, with funds directed toward establishing new research facilities and supporting joint scientific initiatives.

Eli Lilly Commits $250 Million to Expand Purdue University Research Alliance Through 2032

13 days ago

• Eli Lilly has extended its research collaboration with Purdue University through 2032, investing up to $250 million over the next eight years in what could become the largest industry-academic partnership in the United States. • The expanded alliance will facilitate researcher exchanges between Purdue's campus and Lilly's Indianapolis facilities, while also utilizing Indiana's LEAP Research and Innovation District to accelerate drug discovery and development. • This partnership represents a significant investment in pharmaceutical innovation infrastructure, focusing on improving both drug discovery processes and manufacturing capabilities in the U.S.

Lilly and Purdue University Forge Historic $250 Million Pharmaceutical Innovation Partnership

13 days ago

• Eli Lilly and Purdue University have announced a landmark collaboration worth up to $250 million over eight years, potentially becoming the largest industry-academic agreement of its kind in the United States. • The Lilly-Purdue 360 Initiative will focus on accelerating drug discovery through AI, enhancing clinical development pathways, improving manufacturing with robotics, and developing specialized workforce talent. • This expanded partnership, extending through 2032, will create research opportunities across multiple locations including Purdue's campus and Lilly's facilities in Indianapolis and the LEAP Research and Innovation District.

Merck Animal Health Commits $895 Million to Expand Kansas Manufacturing and R&D Facilities

14 days ago

• Merck Animal Health is investing $895 million to expand its manufacturing and research facilities in De Soto, Kansas, marking one of the largest economic development projects in the state's recent history. • The investment is part of Merck's broader commitment to enhance domestic manufacturing capabilities, with over $12 billion allocated since the 2017 Tax Cuts and Jobs Act and an additional $9 billion planned by 2028. • This expansion reinforces Kansas' position as a global leader in animal health, with state officials highlighting the far-reaching economic benefits and job creation potential for the region.

FDA Requests Additional Trial for Novavax COVID-19 Vaccine Before Full Approval

a month ago

• The FDA has asked Novavax to conduct an additional randomized, controlled study of its COVID-19 vaccine NVX-CoV2601 before considering full approval, despite the vaccine having emergency use authorization since 2022. • Interim results from a phase 2/3 study showed Novavax's updated XBB.1.5 variant vaccine generated 5.8 times higher neutralizing antibody levels compared to the original formulation, with a favorable safety profile. • The FDA's request represents a significant setback for Novavax, which had expected approval based on prior conversations with regulators and had already passed its April 1 PDUFA date.

Lilly's Olumiant Shows Promise in Preserving Beta Cell Function in Type 1 Diabetes

a month ago

• Phase 2 BANDIT trial demonstrates Eli Lilly's Olumiant (baricitinib) can slow progression of type 1 diabetes by preserving insulin-producing beta cell function over 48 weeks of treatment. • Patients receiving Olumiant required significantly less insulin therapy and experienced decreased blood glucose fluctuations compared to placebo, potentially reducing treatment burden. • Researchers identify TYK2 inhibition as another promising approach for type 1 diabetes treatment, with an FDA-approved psoriasis drug potentially offering a dual mechanism to protect beta cells and reduce inflammation.

Eradivir Launches Phase 2 Human Challenge Study for Novel Influenza Therapeutic EV25

2 months ago

• Eradivir has initiated a Phase 2 human challenge study for EV25, a novel antiviral therapeutic, following successful Phase 1 results showing the compound was well-tolerated in healthy participants. • The study will evaluate up to 60 healthy adults deliberately infected with influenza, with data expected by September 2025, potentially leading to a larger Phase 2b trial involving 375 participants during the 2025-26 flu season. • Preclinical research demonstrated EV25's ability to eliminate influenza virus in lungs even 96 hours post-infection and effectiveness against multiple flu strains, including pandemic variants and those resistant to current treatments.

Akston Biosciences and Purdue University Launch Immunotherapy Trial for Canine Bladder Cancer

6 months ago

• Purdue University and Akston Biosciences are trialing an anti-cPD-L1 monoclonal antibody to treat canine urothelial carcinoma. • The immunotherapy aims to enhance the immune system's ability to target and destroy cancer cells in dogs with bladder cancer. • The trial assesses the safety, pharmacokinetics, and antitumor effects of the mAb, supported by an NCI grant and Purdue's One Health initiative. • Parallel studies will explore the mAb's effects on anti-tumor immune responses, potentially advancing immunotherapy for both canine and human cancers.

Adipo Therapeutics Presents Promising Preclinical Data for Obesity Treatment ADPO-002NP

6 months ago

• Adipo Therapeutics presented data on ADPO-002NP, a potential obesity treatment, at The Obesity Society annual meeting, showing promise for human translation. • Studies demonstrated that ADPO-002NP increases key browning markers in human fat cells and tissues, supporting its mechanism for mitochondrial biogenesis and activation. • ADPO-002NP uniquely increases energy expenditure by browning white adipose tissue, offering a potential standalone or complementary approach to existing weight loss drugs. • Adipo Therapeutics is seeking $8 million to advance ADPO-002NP to Phase I clinical trials, aiming to demonstrate safety and clinical proof of concept.